Clinical Trials

Study Title

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 (Regeneron 2067)

Purpose

This research study is looking at treatment with Regeneron Monoclonal Antibody Treatment for Covid-19 positive expectant mothers and children.  The study drug targets the virus that causes COVID-19 and may make it harder for the virus to infect you further. The goals of the study include seeing whether the drug reduces the need for medical visits.   ALL QUALIFIED PATIENTS RECEIVE REGENERON MONOCLONAL ANTIBODY TREATMENT.

Eligibility

· Must be pregnant or less than 18 years old

· If less than 18 years old, the child must have a risk factor for developing Covid-19 complications such as Asthma, Diabetes, or BMI > 95th percentile for age and sex based on CDC growth charts.

· Positive Covid test collected within 72 hours of enrollment

· Have symptoms consistent with Covid-19 with an onset within 7 days of enrollment.

You Cannot

· Have a diagnosis with Covid-19 prior to this event.

· Have been admitted to a hospital due to COVID-19 prior to enrollment.

· Have an active infection with flu or other non-SARS-COV-2 respiratory pathogen.

· Received any vaccine for Covid-19.

ENROLLMENT CLOSED

Study Process

· Nasopharyngeal swabs and blood will be collected at select appointments. There will be 6-7 appointments over 6 months.

· No cost to the patient or insurance

· Free Covid-19 testing / treatment

· Patient stipend  

· Single infusion

Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130